A dose-response relationship study of SR141716 [rimonabant] in obese patients.

Trial Profile

A dose-response relationship study of SR141716 [rimonabant] in obese patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2009 Actual patient number (527) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top